About EnginZyme
EnginZyme is a Healthcare company based in Stockholm (Sweden) founded in 2014 by Samuel Hargestam, Karim Engelmark Cassimjee, and Robin Chatterjee. Developer of immobilized enzymes. EnginZyme has raised $42.34 million across 5 funding rounds from investors including SEB, Bunge and European Union. Its chief executive, as recorded, is Aymeric de Gantes. EnginZyme offers products and services including Enzyme Immobilisation Technology and Cell-Free Biomanufacturing. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its legal entity is EnginZyme AB.
Company details
EnginZyme was founded in 2014 in Stockholm, Sweden, within the biotechnology sector. Patented enzyme immobilization technology is utilized to enable enzymes as catalysts in industrial applications. Operations focus on productive enzyme integration across food, cosmetics, and pharmaceutical processes. Core activities support chemical manufacturing efficiency through this specialized approach.
- Headquarters Stockholm, Sweden
- Founders Samuel Hargestam, Karim Engelmark Cassimjee, Robin Chatterjee
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website enginzyme.com
- Social LinkedIn X
- Legal Name Enginzyme Ab
- Total Equity Funding$42.34M (USD)
in 5 rounds
- Latest Funding Round$7.6M (USD), Series B
Sep 2026
- InvestorsSEB
& 6 more
Products & Services of EnginZyme
EnginZyme offers a comprehensive portfolio of products and services, including Enzyme Immobilisation Technology and Cell-Free Biomanufacturing.
Patented method for stable enzymes in sustainable manufacturing processes
Enables efficient chemical production without living organisms using familiar techniques
Funding Insights of EnginZyme
EnginZyme has successfully raised a total of $42.34M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $7.6 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42.34M
- Total Rounds 5
- Last Round Series B — $7.6M
- First Round $332,172
(Jan 2020)
- Investors Count 7
All 5 funding rounds of EnginZyme with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | $7.6M | Series B | – | – | |
| Dec 2022 | $22.22M | Series B | – | Almi, Navigare Ventures | |
| Feb 2021 | $5.58M | Series A | – | Industrifonden | |
| Apr 2020 | $6.94M | Series A | – | Sofinnova Partners | – |
| Jan 2020 | $332,172 | Grant | – | – |
7 investors in total: 7 institutional.
Investors in EnginZyme
EnginZyme has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include SEB, Bunge and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are provided by Almi in seed to growth-stage startups. | 1994 | almi.se | Stockholm, Sweden | |
Navigare Ventures is focused on early-stage science-driven investments. | navigareventures.com | Stockholm, Sweden | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Investments in deep-tech, life sciences, and transformative tech are managed. | industrifonden.com | Stockholm, Sweden | ||
Vertically integrated agribusiness for agro-processing and supply of sugar, food ingredients, and farm inputs | 1818 | bunge.com | White Plains, United States | |
SEB is recognized as a leading Nordic corporate bank. | 1856 | sebgroup.com | Stockholm, Sweden | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for EnginZyme
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EnginZyme
21 people are tracked at EnginZyme (10 in leadership, 4 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Samuel Hargestam | Co-Founder | Leadership |
Karim Engelmark Cassimjee | Co-Founder & CIO | Leadership |
Robin Chatterjee | Co-Founder | Leadership |
Aymeric de Gantes | CEO | Leadership |
Samuel Härgestam | COO & Co-Founder | Leadership |
Javier Ibáñez Abad | Director - Process Engineering | Leadership |
Karl Johan Tärbe | Sr Director Business Development | Leadership |
Federica Ruggieri | Associate Director Product Development | Leadership |
Mónica Guevara Martínez | Director Of Enzyme Engineering | Leadership |
Marco Antonio Saucedo | Vice President R&d | Leadership |
Michael Krel | Chairman | Board & advisors |
Frederique Lafosse | Board Member | Board & advisors |
Martin Randel | Board Member | Board & advisors |
Patrik Sobocki | Board Member | Board & advisors |
David Lloyd | Senior Lab Automation Engineer | Team |
Alexey Volkov | Commercial Development Lead, Industrial Biocatalysts | Team |
Dóra Vitay | Senior Lab Automation & Data Engineer | Team |
Natália Alvarenga da Silva | Lead Researcher | Team |
Adriana Freites | Senior Project Manager | Team |
Elin Stridfeldt | Senior R&d Project Manager | Team |
1 more people are available in the full profile.
Complete people profiles for EnginZyme
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EnginZyme
3 dated milestones of EnginZyme across 12 years, from founding to its latest funding, stage changes and deals.
- Founded EnginZyme is founded.
- Funding First funding round of $332K.
- Funding Latest funding round, Series B, of $7.6M.
Web traffic of EnginZyme
Websites that share an audience with EnginZyme (enginzyme.com).
Websites whose visitors overlap most with EnginZyme. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| saiwa.ai | 100% | #1,613,672 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enginzyme
Complete news archive for EnginZyme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EnginZyme
EnginZyme was founded in 2014 and raised its 1st funding round 6 years after it was founded.
EnginZyme is headquartered in Stockholm, Sweden.
Aymeric de Gantes is the CEO of EnginZyme, as recorded in our data.
EnginZyme is a funded company, having raised a total of $42.34M across 5 funding rounds to date. The company's 1st funding round was a Grant of $332.17K, raised on Jan 2020.
EnginZyme was founded in 2014 in Stockholm, Sweden, within the biotechnology sector. Patented enzyme immobilization technology is utilized to enable enzymes as catalysts in industrial applications. Operations focus on productive enzyme integration across food, cosmetics, and pharmaceutical processes. Core activities support chemical manufacturing efficiency through this specialized approach.
EnginZyme offers Enzyme Immobilisation Technology and Cell-Free Biomanufacturing.
EnginZyme has 7 investors. Key investors include SEB, Bunge, European Union, Almi, and Navigare Ventures.
EnginZyme operates through Enginzyme Ab.